Dementia to cost nation $321 billion this year, Alzheimer’s Association says
By
Kimberly Bonvissuto
Mar 16, 2022
This year, Alzheimer’s and other dementias will cost the nation $321 billion, increasing to $1 trillion by 2050, according to a report released Tuesday by the Alzheimer’s Association.
NIH requests additional $321M for Alzheimer’s, dementia research
By
Kimberly Bonvissuto
Aug 02, 2022
The National Institutes of Health has requested an additional $321 million in fiscal year 2024 for research into Alzheimer’s and other dementias.
Industry advocates join coalition to support federal bill requiring use of Alzheimer’s detection tools
By
Kimberly Bonvissuto
Oct 04, 2023
A bipartisan bill requiring the use of cognitive impairment detection tools in the early detection of Alzheimer’s disease and related dementias has the support of the senior living industry.
3 new dementia studies of note
Oct 27, 2015
New research quantifies costs associated with dementia care compared with other diseases and offers a little good news for those with Lewy body dementia or Alzheimer’s disease.
Alzheimer’s Association asks CMS to provide full coverage of FDA-approved dementia drugs
By
Kimberly Bonvissuto
Dec 21, 2022
Every day, more than 2,000 older adults living with mild dementia may transition to a more advanced stage of the disease and no longer be eligible for lecanemab and other antibodies targeting amyloid under...
Home gaining on LTC as final residence for those with Alzheimer’s
By
Lois A. Bowers
May 25, 2017
The majority of people with Alzheimer’s disease die in long-term care facilities, although the percentage is decreasing, whereas the number of people with the disease who die at home is increasing,...
Alzheimer’s cure would result in assisted living losses of $16 billion in annual revenues, 110,000...
By
Lois A. Bowers
Sep 17, 2019
A “novel, simple and fast-acting” cure for Alzheimer’s disease would be a “medical miracle” but would result in a loss of $16.3 billion in annual revenues for the assisted living industry, according...
Medicare will only cover Aduhelm for patients in clinical trials
Apr 08, 2022
The decision is meant to protect patients while gathering more clinical data on whether the medication actually helps slow declines in thinking.
Alzheimer’s experts throw support behind experimental drug despite adverse events, deaths
By
Kimberly Bonvissuto
Dec 01, 2022
Alzheimer’s disease experts are throwing their support behind the drug lecanemab, despite reports of two deaths tied to the experimental monoclonal antibody medication.
An episodic approach to Alzheimer’s
By
Anna Fisher
Dec 01, 2014
For so many of us working in senior care, we are often approached by family members and caregivers with questions about the uncertainty of the dementia journey.